| Trial ID: | L6821 |
| Source ID: | NCT00268645
|
| Associated Drug: |
Insulin Glargine
|
| Title: |
Insulin Glargine in Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Insulin Glargine
|
| Outcome Measures: |
Primary: For efficacy: FBG (Fasting Blood Glucose), HbA1c | Secondary: For safety: ICA (Insulin Cell Antibody)
|
| Sponsor/Collaborators: |
Sponsor: Sanofi
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
534
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2004-09
|
| Completion Date: |
|
| Results First Posted: |
|
| Last Update Posted: |
2011-01-11
|
| Locations: |
Sanofi-Aventis, Istanbul, Turkey
|
| URL: |
https://clinicaltrials.gov/show/NCT00268645
|
